Table 1.

Published cases using adjuvant topical amphotericin following surgical exenteration, enucleation, or craniotomy for rhino-orbital-cerebral mucormycosis (ROCM).

Reference	Age/Sex	Risk Factors	Species	IV Therapy	Topical Route	Topical Solution	Frequency	Outcome	Final Margins
Mohsenipour 1996, Austria [12]	65 M	Immuno-suppression	Rhizomucor spp	dAMB, then L-AMB	Pack with absorbable gelatin sponge	dAMB 2.5 mg/cm3	Once	Lived	n/a
Seiff, 1999, USA [23]	34 M	Diabetes, Immuno-suppression	Mucor spp	dAMB	Irrigation catheter into orbit	dAMB 0.25–1 mg/mL	TID-QID x 5–14 days	Lived	n/a
Farooq, 2015, USA [24]	59 F	Diabetes, Immuno-suppression	n/a	dAMB + Micafungin	Drip into orbit	n/a	n/a	Died	n/a
Uğurlu, 2015, Turkey [25]	59 M	Diabetes	n/a	L-AMB	Direct Irrigation into socket	n/a	n/a	Lived	n/a
Liu, 2019, China [26]	50 F	Immuno-suppression	Cunninghamella	L-AMB + Posaconazole	Nasal irrigation	dAMB 0.08 mg/mL	BID	Died	n/a
Navarro-Perea, 2019, Spain [27]	50 F	Immuno-suppression	Rhizopus oryzae	L-AMB + Andulafungin	Impregnated gauze	L-AMB	BID x 7 days, then daily	Lived	n/a
Navarro-Perea, 2019, Spain [27]	52 F	Diabetes	Rhizopus oryzae	L-AMB + Andulafungin	Impregnated gauze	L-AMB	BID x 7 days, then daily	Lived	n/a